

in VIROLOGY			
-	7th. European Seminars in Virology (EuSeV) 2019		
	Program		
FRIDAY 14.06.2019			
13:45-14:00	Welcome		
	Dana Wolf, Gabriella Campadelli-Fiume, Thomas Mertens, Michael Kann Giorgio Palù		
Session on Ethical and technological issues about antiviral vaccine and antibodies development Chair: Giorgio Palù			
14:00-14:40	Andrea Grignolio, Cognitive bases for vaccine hesitancy Medical Humanities & Bioethics, Vita-Salute San Raffaele University, Milan, Italy grignolio.andrea@hsr.it		
14:40-15:20	Rino Rappuoli, Reverse vaccinology 2.0 GSK, Siena, Italy rino.r.rappuoli@gsk.com		
15:20-16:00	Melvin Kohn, MSD's Investigational Ebola Vaccine Regional Director of Medical Affairs Lead for Vaccines, MSD. melvin.kohn@msd.com		
16:00-16:30	Discussion		
16:30-17:30	Selected oral presentations		
	Matti Sallberg, DNA-based prime-boost active immunotherapy to induce a functional cure in patients with chronic hepatitis B		
	Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, Laboratory Medicine, Karolinska University Hospital Huddinge, Stockholm		
	Francesco Santoro, Human transcriptomic response to vaccination with recombinant VSV expressing Ebola virus Glycoprotein		
	Laboratory of Molecular Microbiology and Biotechnology (LAMMB), Dept. of Medical Biotechnologies, University of Siena, Italy		
	Matteo Castelli, HCV/E2 dynamics controls overall sensitivity to neutralization Laboratory of Microbiology and Virology, Università "Vita-Salute" San Raffaele, Milan, Italy		
	Francesco Nicoli, Poor responsiveness of naïve CD8+ T-cells from elderly individuals is associated to their altered basal metabolism Sorbonne Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI- Paris), Paris, France - Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy Dhanik Reshamwala, Novel anti-virals against Enteroviruses		
	Dhank Reshamwala, Novel anti-vitals against Enterovituses Department of Biological and Environmental Science, Nanoscience Center, University of Jyväskylä, Finland		

17:30-18:00

DISCUSSIONS IN FRONT OF POSTERS

20:00 Dinner

SATURDAY 15.06.2019

Regulatory and technological issues about antiviral vaccine and antibodies development

Chair: Thomas Mertens & Gabriella Campadelli Fiume

09:00-09:40	Guido Silvestri, Towards an HIV vaccine: recent advances from studies in non-human primates
	Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, USA, gsilves@emory.edu
09:40-10:20	Christian Sinzger, CMV-Elite-neutralizing Antibodies Institute of Virology, University of Ulm, Ulm, Germany, christian.sinzger@uniklinik-ulm.de
10:20-11:00	Gabriella Campadelli Fiume, Oncolytic herpes simplex viruses elicit antigen agnostic vaccine-like anticancer protection Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna,
	Bologna, Italy, gabriella.campadelli@unibo.it
11:00-11:30	Break
11:30-12:10	Thomas Mertens, The art of vaccine recommendations in the real world Institute of Virology, Ulm University Medical Center, Ulm, Germany, thomas.mertens@uni-
	ulm.de
12:10-13:30	Selected oral presentations
	Alberto Reale, Oncolytic HSV-1 vectors for in situ vaccination against solid tumours
	Department of Molecular Medicine, University of Padua
	Greta Forlani, HTLV-1 Tax and HBZ oncoproteins expression and subcellular localization in infection and disease progression: implications for immune-based therapeutic approaches
	Laboratories of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Surgery, University of Insubria, Varese, Italy
	Anna Czarnota, Characterization of anti-hepatitis C neutralizing antibody response after immunization with chimeric hepatitis B/hepatitis C virus like particles.
	Laboratory of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology of the University of Gdańsk and Medical University of Gdańsk
	Nir Paran, Antibody Treatment of Smallpox Vaccine Adverse Events
	Department of Infectious diseases, Israel Institute for Biological Research (IIBR), Ness-Ziona, Israel
	Carlo De Giuli Morghen, A recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine
	Catholic University "Our Lady of Good Counsel" Tirana, Albania, Department of Medical Biotechnologies and Translational Medicine, Univ. of Milan, Italy
	Salomon Ferdinand, An Orf virus-based platform technology for vaccine development using a modulatory brick system
	University Tuebingen, Interfaculty Institute for Cell Biology, Department for Immunology, Tuebingen, Germany
13:30-15:00	Lunch break

Developmer	Development of vaccines and antibodies against viral infection		
Chair: Dana	Chair: Dana Wolf		
15:00-15:40	Ali Mirazimi, Development of vaccine against Crimean Congo Hemorrhagic Fever; Past and Future Department of Laboratory Medicine, Karolinska University Hospital and KI, Stockholm, Sweden. Ali.Mirazimi@ki.se		
15:40-16:20	Arnaud Marchant, Maternal and neonatal immunization Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium, arnaud.marchant@ulb.ac.be		
16:20-17:00	Frédéric Tangy, Vaccines against Ebolavirus and other emerging viruses Viral Genomics and Vaccination Unit, Institut Pasteur, Paris, France, ftangy@pasteur.fr		
17:00-17:20	Break		
17:20-18:00	Florian Klein, HIV-Super-neutralizing Antibodies		
	Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. florian.klein@uk-koeln.de		
18:00-19:00	Selected oral Presentations		
	Eberhard Hildt, Development of a new vaccine platform for induction of a robust B- and T-cell response against viral infections		
	Paul-Ehrlich-Institut, Department of Virology, Langen, Germany; German Center for Infection Research (DZIF), Braunschweig		
	Benjamin Gutjahr, Monoclonal antibodies protect mice in Rift Valley fever challenge model		
	Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases (INNT), Greifswald – Isle of Riems, Germany		
	Ola Blixt, Efficient identification of immunodominant (glyco-)peptides for type- specific serology and monoclonal antibody developments		
	Department of Chemistry, University of Copenhagen, Frederiksberg C, Denmark		
	Sofia Appelberg, Protection Against Crimean-Congo Hemorrhagic Fever Virus Infection in Mice After Immunization with DNA Plasmids Coding for Different Viral Proteins		
	Public Health Agency of Sweden, Stockholm		
	Anna Lucia Tornesello, Humoral immune response to HCV peptides as cancer-progression biomarkers of HCV-infections		
	Istituto Nazionale Tumori – IRCCS Fondazione Pascale, Naples, Italy		
20:00 Dinner	r		

SUNDAY 16.06.2019		
Success and failure of antiviral vaccine development		
Chair: Michael Kann		
9:00-9:40	John J. Skehel, Experimental uses and roles in immunity of antibodies that recognize influenza haemagglutinin	
	Francis Crick Institute, London, UK, John.Skehel@crick.ac.uk	
09:40-10:20	Emanuele Montomoli, Present and future of anti-influenza vaccinations	
	Department of Molecular and Developmental Medicine, University of Siena, Italy, Emanuele.montomoli@unisi	
10:20-11:00	Wolfgang Hammerschmidt, Towards an EBV vaccine	

	Research Unit Gene Vectors, Helmholtz Zentrum München, Germany, hammerschmidt@helmholtz-muenchen.de	
11:00-11:40	Sergio Abrignani, Why is it too difficult to develop a vaccine against HCV INGM, Milan, Italy, abrignani@ingm.org	
11:40-12:20	Giorgio Palù, Clinically and experimentally adopted vaccines against Flavivirus infections and Dengue	
	Department of Molecular Medicine, University of Padova, Italy, giorgio.palu@unipd.it	
12:20 Closing Remarks and Brunch		

.